Septodont Holding patents expiration
1. Oraverse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6872390 | SEPTODONT HOLDING | Local anesthetic methods and kits |
May, 2021
(2 years ago) | |
| US6764678 | SEPTODONT HOLDING | Local anesthetic methods and kits |
May, 2021
(2 years ago) | |
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jul, 2023
(8 months ago) | |
| US7229630 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jul, 2023
(8 months ago) | |
| US7569230 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct, 2023
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 18, 2019 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 09 May, 2008
Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic
Dosage: INJECTABLE;INJECTION
More Information on Dosage
ORAVERSE family patents
